LS2D617

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLS2D617
Drug Alias NameLS2D617 (Hybritech)LS2D617
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSmall Cell Lung CarcinomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A